(59 days)
Exempt from 510k
No
The summary does not mention AI, ML, or related terms, and the performance studies focus on electroacoustic and EMC testing, not AI/ML model validation.
Yes
The Ponto 4 sound processors are intended to amplify sound for individuals with hearing loss, which is a therapeutic function aimed at improving a patient's condition.
No
Explanation: The device is described as a sound processor for hearing, and its intended use is to amplify sound for individuals with specific types of hearing loss. It functions as a treatment or assistive device, not a diagnostic one. The text describes how it helps patients hear, not how it identifies or diagnoses a condition.
No
The device description explicitly states that the system consists of a sound processor connected to an implant with a skin penetrating abutment, which are physical hardware components. The performance studies also detail testing of electroacoustic and EMC performance, and firmware validation, indicating hardware-software integration.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Ponto 4 sound processor is a bone-anchored hearing system. It works by transmitting sound vibrations directly to the cochlea through the skull bone to improve hearing.
- Lack of Biological Sample Analysis: The device does not analyze any biological samples from the patient. Its function is to process and transmit sound.
Therefore, the Ponto 4 sound processor falls under the category of a medical device, specifically a hearing aid system, rather than an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The Ponto 4 sound processors are intended for improvement of hearing for patients with conductive and mixed hearing losses, bilateral fitting and single sided deafness.
Ponto 4 sound processors are intended for the following patients and indications:
· Patient with conductive or mixed hearing losses, who can still benefit from amplification of the sound. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear should be better than or equal to 45 dB HL for use with the Ponto 4 sound processor.
· Bilateral fitting is applicable for most patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2 and 4 kHz, or less than 15 dB at individual frequencies.
· Patients who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. single sided deafness or "SSD"). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz).
· Also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
The placement of a bone anchored implant is contraindicated for patient below the age of 5.
The Ponto 4 sound processors are intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS) (refer to the Ponto 4 labeling for specific compatible Cochlear models). In addition, selected Cochlear Baha sound processors can be used with the Ponto implant/abutment system (refer to the Ponto labeling for compatible Baha sound processor models).
Product codes
LXB, MAH
Device Description
A bone anchored hearing system consists of a sound processor connected to an implant with a skin penetrating abutment. The implant is surgically anchored in the skull bone behind the ear. Vibrations generated by the sound processor are transmitted via the implant directly through the skull bone to the cochlea as bone conduction sound processor has a coupling so that it can be easily connected to and disconnected from the abutment by the user. Alternatively, it can be connected to head band accessories, to function as a conventional bone conductor. Using a computer based fitting system the sound processor can be adjusted to the patient's individual hearing requirements. The Ponto family is intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skull bone behind the ear
Indicated Patient Age Range
The placement of a bone anchored implant is contraindicated for patient below the age of 5.
Intended User / Care Setting
The sound processor is individually adjusted to the patient audiogram and needs by the Genie Medical fitting software by the audiologist.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Testing of the Ponto 4 sound processors includes electroacoustic and EMC performance testing and firmware validation. These tests include: Maximum output responses. Output for full-on gain at 50 dB SPL and 60 dB SPL, Equivalent input noise level, Total harmonic distortion, Frequency range, Battery voltage, Current Consumption, Battery lifetime, IRIL (input related interference level) and Processing delay, i.e. electro acoustical testing.
Ponto 4 sound processors have also been tested to (1) not emit excessive amounts of electromagnetic energy (EMC emissions); (2) operate as intended without performance degradation in the presence of an electromagnetic disturbance (EMC immunity) and ESD.
The above-mentioned tests verify that the Ponto 4 sound processors are as safe and efficient as the Ponto 3 sound processors. In all instances, the Ponto 4 sound processors functioned and the performance observed was as expected.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Exempt from 510k
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 874.3302 Bone-conduction hearing aid.
(a)
Identification. A bone-conduction hearing aid is a wearable sound-amplifying device intended to compensate for impaired hearing and that conducts sound to the inner ear through the skull. The non-implantable components of a bone-conduction hearing aid, such as the external sound processor, are subject to the requirements in § 801.422 of this chapter.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 6, 2019
Oticon Medical AB Lise Terkelsen Regulatory Affairs Manager Datavagen 37 B Askim, SE-436 32 Se
Re: K190540
Trade/Device Name: Ponto 4 Regulation Number: 21 CFR 874.3300 Regulation Name: Hearing Aid, Bone Conduction, Implanted Regulatory Class: Class II Product Code: LXB, MAH Dated: February 28, 2019 Received: March 4, 2019
Dear Lise Terkelsen:
This letter corrects our substantially equivalent letter of May 2, 2019.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Shu-Chen Peng
for Michael Ryan Director DHT1C: Division of ENT, Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K190540
Device Name Ponto 4
Indications for Use (Describe)
Ponto 4 sound processors are intended for the following patients and indications:
· Patient with conductive or mixed hearing losses, who can still benefit from amplification of the sound. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear should be better than or equal to 45 dB HL for use with the Ponto 4 sound processor.
· Bilateral fitting is applicable for most patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2 and 4 kHz, or less than 15 dB at individual frequencies.
· Patients who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. single sided deafness or "SSD"). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz).
· Also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
The placement of a bone anchored implant is contraindicated for patient below the age of 5.
The Ponto 4 sound processors are intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS) (refer to the Ponto 4 labeling for specific compatible Cochlear models). In addition, selected Cochlear Baha sound processors can be used with the Ponto implant abutment system (refer to the Ponto labeling for compatible Baha sound processor models).
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | |
|---|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW. The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
Ponto 4
Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared
| Submitter name: | Oticon Medical AB |
|---|---|
| Address: | Datavägen 37 B |
| SE-436 32 Askim | |
| Sweden | |
| Phone: | +46 31 748 61 00 |
| Facsimile: | +46 31 687 756 |
| Contact Person: | Lise Terkelsen |
| Mobile phone: | +45 24 22 51 46 |
| Date Prepared: | May 1, 2019 |
Name of Device and Name/Address of Manufacturer
Ponto 4
Oticon Medical AB Datavägen 37 B SE-436 32 Askim Sweden
Common or Usual Name: Ponto bone anchored hearing system
Classification Name: Hearing aid, bone conduction
Classification Regulation: 21 C.F.R. §874.3300 (Product codes LXB, MAH)
Predicate Devices
| Device | 510(k) no. | Manufacturer |
|---|---|---|
| Predicate device: Ponto 3 | K161671 | Oticon Medical AB |
| Reference device: Oticon Opn S™ air | ||
| conduction hearing aid with Bluetooth | ||
| wireless connectivity | Exempt from 510k | Oticon A/S |
4
Device Description
A bone anchored hearing system consists of a sound processor connected to an implant with a skin penetrating abutment. The implant is surgically anchored in the skull bone behind the ear. Vibrations generated by the sound processor are transmitted via the implant directly through the skull bone to the cochlea as bone conduction sound processor has a coupling so that it can be easily connected to and disconnected from the abutment by the user. Alternatively, it can be connected to head band accessories, to function as a conventional bone conductor. Using a computer based fitting system the sound processor can be adjusted to the patient's individual hearing requirements. The Ponto family is intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS).
Intended Use / Indications for Use
Intended use
The Ponto 4 sound processors are intended for improvement of hearing for patients with conductive and mixed hearing losses, bilateral fitting and single sided deafness.
Indications for use
Ponto 4 sound processors are intended for the following patients and indications:
· Patient with conductive or mixed hearing losses, who can still benefit from amplification of the sound. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear should be better than or equal to 45 dB HL for use with the Ponto 4 sound processor.
· Bilateral fitting is applicable for most patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2 and 4 kHz, or less than 15 dB at individual frequencies.
• Patients who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. single sided deafness or "SSD"). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz).
• Also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
The placement of a bone anchored implant is contraindicated for patient below the age of 5.
The Ponto 4 sound processors are intended to be used with either the Ponto implant system or with specific compatible BAHA abutments/implants from Cochlear Bone Anchored Solutions (BAS) (refer to the Ponto 4 labeling for specific compatible Cochlear models). In addition, selected Cochlear Baha sound processors can be used with the Ponto implant/abutment system (refer to the Ponto labeling for compatible Baha sound processor models).
5
Technological Characteristics
The Ponto 4 is a modification of the previously cleared sound processors (the Ponto 3, Power and Ponto 3 SuperPower in K161671), more specifically the Ponto 3 model, and represents the latest sound processor model in the Ponto bone anchored hearing system.
The Ponto 4 sound processor incorporates Velox S platform that is also used in the reference Oticon Opn S™ air conduction hearing aid legally marketed as class II, 510(k)-exempt devices. The Velox S platform introduces wireless 2.4 GHz Bluetooth connectivity and minor changes to the sound processing features. compared to the predicate Ponto 4 is smaller in size, which is enabled by moving the user controls to wireless accessories from Oticon A/S, and by smaller transducer and battery. Ponto 4 has a tamper resistant exchangeable battery drawer, side-neutral design, and a LED indicating status (e.g. low battery) of the sound processor.
The Ponto 4 housing and coupling are made of medical grade plastics that have been shown to be biocompatible and safe for human use.
This submission also includes minor modifications to the previously cleared accessory Genie Medical fitting software, and addition of compatibility with wireless accessories from Oticon A/S.
Discussion of testing
Testing of the Ponto 4 sound processors includes electroacoustic and EMC performance testing and firmware validation.
The Ponto 4 hardware is similar to Ponto 3 hardware, though smaller in size enabled by a smaller transducer and battery. The sound processing platform has been updated and a series of tests were conducted on the Ponto 4 sound processors to verify the design criteria and device performance with respect to electro acoustical performance. These tests include: Maximum output responses. Output for full-on gain at 50 dB SPL and 60 dB SPL, Equivalent input noise level, Total harmonic distortion, Frequency range, Battery voltage, Current Consumption, Battery lifetime, IRIL (input related interference level) and Processing delay, i.e. electro acoustical testing.
Ponto 4 sound processors have also been tested to (1) not emit excessive amounts of electromagnetic energy (EMC emissions); (2) operate as intended without performance degradation in the presence of an electromagnetic disturbance (EMC immunity) and ESD.
The above-mentioned tests verify that the Ponto 4 sound processors are as safe and efficient as the Ponto 3 sound processors. In all instances, the Ponto 4 sound processors functioned and the performance observed was as expected. Hence, we have come to the conclusion that further testing will not raise new issues of safety and efficacy.
Substantial Equivalence
The Ponto 4 sound processors have the same intended use as the Ponto 3 sound processor in K161671.
Ponto 4 sound processors have the similar principles of operations as the Ponto 3 sound processors. The sound processor is connected via an abutment to an implant placed in the temporal bone behind the ear, and the vibrations from the sound processor are transmitted directly to the inner ear through bone conduction. The implant and abutment are installed by a surgical procedure, and the sound processor can be connected and disconnected by the user by the snap coupling.
6
The sound processor is individually adjusted to the patient audiogram and needs by the Genie Medical fitting software by the audiologist. The volume and listening program can be changed by the user. On the predicate Ponto 3 sound processors this is done either on the sound processor itself or via the wireless accessories, whereas on the Ponto 4 the user can change the volume and program by using wireless accessories only. The same wireless remote functions are available for the predicate Oticon A/S 's Oticon S™ air conduction hearing aids, legally marketed as class II, 510(K)-exempt devices.
The sound processing platform and the wireless technology in the Ponto 4 sound processors are the same as those used in the legally marketed, class II 510(k)-exempt Oticon A/S air conduction hearing aids. The maximum force output and gain of the Ponto 4 sound processor are equivalent to those provided by the predicate Ponto 3 sound processors.
7
Comparison table
| | Ponto 4 | Ponto 3
(K161671) | Oticon Opn S™ air
conduction hearing aid
with wireless
technology
(legally marketed, class II
510(k)-exempt) |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | Improvement of hearing for patients
with conductive and mixed hearing
losses, whether unilaterally or
bilaterally fitted or for those with single
sided deafness. | Same | To amplify and transmit
sound to the ear and hereby
compensate for impaired
hearing. Indicated for hearing
losses within mild-to- severe-
to-profound range. |
| Indications for
Use | • Patient with conductive or mixed
hearing losses, who can still benefit
from amplification of the sound. The
pure tone average (PTA) bone
conduction (BC) threshold (measured
at 0.5, 1, 2 and 3 kHz) of the indicated
ear should be better than or equal to
45 dB HL for use with the Ponto 4
sound processor.
• Bilateral fitting is applicable for most
patients having a symmetrically
conductive or mixed hearing loss. The
difference between the left and right
sides' BC thresholds should be less
than 10 dB on average measured at
0.5, 1, 2 and 4 kHz, or less than 15 dB
at individual frequencies.
• Patients who have a profound
sensorineural hearing loss in one ear
and normal hearing in the opposite
ear (i.e. single sided deafness or
"SSD"). The pure tone average (PTA)
air conduction (AC) threshold of the
hearing ear should then be better than
or equal to 20 dB HL (measured at
0.5, 1, 2 and 3 kHz).
• Also indicated for any patient who is
indicated for an air-conduction
contralateral routing of signals (AC
CROS) hearing aid, but who for some
reason cannot or will not use an AC
CROS.
The placement of a bone anchored
implant is contraindicated for patient
below the age of 5.
The Ponto 4 sound processors are
intended to be used with either the
Ponto implant system or with specific
compatible BAHA abutments/implants
from Cochlear Bone Anchored
Solutions (BAS) (refer to the Ponto 4
labeling for specific compatible
Cochlear models). In addition,
selected Cochlear Baha sound | Same | N/A |
| Sound
processing
features | processors can be used with the
Ponto implant/abutment system (refer
to the Ponto 4 labeling for compatible
Baha sound processor models). | | |
| | Open Sound Navigator Clear Dynamics Transient Noise Management Feedback Shield (LX) 64 Processing channels Speech Guard LX Wind noise management Battery management system Fitting bandwidth of 10 kHz | Free Focus Multiband adaptive directionality Tri-state noise reduction Inium Sense feedback shield 15 sound processing channels Speech Guard Wind noise reduction Binaural processing Battery management system | Same (+ additional) |
| Fitting features | 16 channel frequency response shaping BC In-situ Audiometry Feedback Analyser OpenSound - Transition OpenSound - Noise reduction controls Wireless connection during fitting Data Logging Technical Measurement tool Verification tool FLogram Wireless accessories setting tool Visual indicators setting | 10 channel frequency response shaping BC In-situ Audiometry Feedback Manager Data Logging Technical Measurement tool Verification tool Streamer Settings tool (wireless accessory) Fitting Assistant tool FLogram | 16 channel frequency response shaping In-situ Audiometry Feedback Analyser OpenSound - Transition OpenSound - Noise reduction controls Wireless connection during fitting Wireless accessories setting tool Visual indicators setting |
| Wireless
receiver /
transducer | Receiver and transmitter, 2.4 GHz, Bluetooth | Receiver and transmitter, 3.84 Mhz, Oticon proprietary NearLink | Two wireless technologies with the commercial name TwinLink:
Receiver and transmitter, 2.4 GHz, Bluetooth
Receiver and transmitter, 3.84 MHz, Oticon proprietary NearLink |
| Coupling | Material: PEEK Snap coupling outside the abutment | Same | N/A |
| Accessories | Oticon Medical accessories: Head band, test band, soft band and SoundConnector Genie Medical BAHS fitting software, version 2019.1 Skins for personalization Compatible wireless Oticon A/S accessories: Oticon ON App Remote control 3.0 ConnectClip TV Adapter 3.0 EduMic | Head band, test band, soft band and SoundConnector Genie Medical fitting software, version 2016.1 Skins for personalization Compatible wireless Oticon A/S accessories: Connectline App Oticon Medical Streamer Compatible wireless Oticon A/S accessories through the Oticon Medical Streamer: Connectline TV Adapter Connectline microphone Connectline phone adapter | Genie 2 fitting software Oticon ON App Remote control 3.0 ConnectClip TV Adapter 3.0 EduMic |
| Safety
Features | Tamper proof battery drawer Maximum coupling safety release force | Tamper proof battery drawer Maximum coupling safety release force | N/A |
8
9
Conclusion
The minor technological differences between the Ponto 4 sound processors and their predicate devices raise no new issues of safety or effectiveness. Performance data demonstrate that the Ponto 4 sound processors are as safe and effective as the Ponto 3 sound processors. Thus, the Ponto 4 sound processors are substantially equivalent.